Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications.

IF 5.7 2区 医学 Q1 Medicine
Cancer Science Pub Date : 2025-01-16 DOI:10.1111/cas.16455
Yuko Chikaishi, Hiroshi Matsuoka, Eiji Sugihara, Mayu Takeda, Makoto Sumitomo, Seiji Yamada, Gaku Inaguma, Yusuke Omura, Yeongcheol Cheong, Yosuke Kobayashi, Masaya Nakauchi, Junichiro Hiro, Koji Masumori, Koki Otsuka, Hiroshi Nishihara, Koichi Suda, Hideyuki Saya, Tetsuya Takimoto
{"title":"Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications.","authors":"Yuko Chikaishi, Hiroshi Matsuoka, Eiji Sugihara, Mayu Takeda, Makoto Sumitomo, Seiji Yamada, Gaku Inaguma, Yusuke Omura, Yeongcheol Cheong, Yosuke Kobayashi, Masaya Nakauchi, Junichiro Hiro, Koji Masumori, Koki Otsuka, Hiroshi Nishihara, Koichi Suda, Hideyuki Saya, Tetsuya Takimoto","doi":"10.1111/cas.16455","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is well characterized in terms of genetic mutations and the mechanisms by which they contribute to carcinogenesis. Mutations in APC, TP53, and KRAS are common in CRC, indicating key roles for these genes in tumor development and progression. However, for certain tumors with low frequencies of these mutations that are defined by tumor location and molecular phenotypes, a carcinogenic mechanism dependent on BRAF mutations has been proposed. We here analyzed targeted sequence data linked to clinical information for CRC, focusing on tumors with a high tumor mutation burden (TMB) in order to identify the characteristics of associated mutations, their relations to clinical features, and the mechanisms of carcinogenesis in tumors lacking the major driver oncogenes. Analysis of overall mutation frequencies confirmed that APC, TP53, and KRAS mutations were the most prevalent in our cohort. Compared with other tumors, TMB-high tumors were more frequent on the right side of the colon, had lower KRAS and higher BRAF mutation frequencies as well as a higher microsatellite instability (MSI) score, and showed a greater contribution of a mutational signature associated with MSI. Ranking of variant allele frequencies to identify genes that play a role early in carcinogenesis suggested that mutations in genes related to the DNA damage response (such as ATM and POLE) and to MSI (such as MSH2 and MSH6) may precede BRAF mutations associated with activation of the serrated pathway in TMB-high tumors. Our results thus indicate that TMB-high tumors suggest that mutations of genes related to mismatch repair and the DNA damage response may contribute to activation of the serrated pathway in CRC.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cas.16455","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer (CRC) is well characterized in terms of genetic mutations and the mechanisms by which they contribute to carcinogenesis. Mutations in APC, TP53, and KRAS are common in CRC, indicating key roles for these genes in tumor development and progression. However, for certain tumors with low frequencies of these mutations that are defined by tumor location and molecular phenotypes, a carcinogenic mechanism dependent on BRAF mutations has been proposed. We here analyzed targeted sequence data linked to clinical information for CRC, focusing on tumors with a high tumor mutation burden (TMB) in order to identify the characteristics of associated mutations, their relations to clinical features, and the mechanisms of carcinogenesis in tumors lacking the major driver oncogenes. Analysis of overall mutation frequencies confirmed that APC, TP53, and KRAS mutations were the most prevalent in our cohort. Compared with other tumors, TMB-high tumors were more frequent on the right side of the colon, had lower KRAS and higher BRAF mutation frequencies as well as a higher microsatellite instability (MSI) score, and showed a greater contribution of a mutational signature associated with MSI. Ranking of variant allele frequencies to identify genes that play a role early in carcinogenesis suggested that mutations in genes related to the DNA damage response (such as ATM and POLE) and to MSI (such as MSH2 and MSH6) may precede BRAF mutations associated with activation of the serrated pathway in TMB-high tumors. Our results thus indicate that TMB-high tumors suggest that mutations of genes related to mismatch repair and the DNA damage response may contribute to activation of the serrated pathway in CRC.

tmb -高结直肠癌的突变分析:分子途径和临床意义。
结直肠癌(CRC)在基因突变及其致癌机制方面具有很好的特征。APC、TP53和KRAS突变在结直肠癌中很常见,表明这些基因在肿瘤发生和进展中起关键作用。然而,对于某些由肿瘤位置和分子表型定义的这些突变频率较低的肿瘤,已经提出了依赖于BRAF突变的致癌机制。我们在此分析了与CRC临床信息相关的靶向序列数据,重点关注具有高肿瘤突变负担(TMB)的肿瘤,以确定相关突变的特征,它们与临床特征的关系,以及缺乏主要驱动癌基因的肿瘤的致癌机制。总体突变频率分析证实,APC、TP53和KRAS突变在我们的队列中最为普遍。与其他肿瘤相比,tmb -高肿瘤多发于结肠右侧,KRAS较低,BRAF突变频率较高,微卫星不稳定性(microsatellite instability, MSI)评分较高,与MSI相关的突变特征贡献更大。对变异等位基因频率进行排序,以确定在癌变早期发挥作用的基因,这表明与DNA损伤反应相关的基因(如ATM和POLE)和与MSI相关的基因(如MSH2和MSH6)的突变可能先于与tmb高肿瘤中锯齿状通路激活相关的BRAF突变。因此,我们的研究结果表明,高tmb肿瘤表明,与错配修复和DNA损伤反应相关的基因突变可能有助于CRC中锯齿状通路的激活。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Science
Cancer Science ONCOLOGY-
CiteScore
9.90
自引率
3.50%
发文量
406
审稿时长
17 weeks
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信